← Eichor
Study identifier: NCT07377175 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.

Condition: Smallpox · Cowpox · Monkeypox  ·  Sponsor: China National Biotec Group Company Limited

PhasePhase 1
Planned participants76
Who can joinAll sexes, 18 Years to 50 Years
Healthy volunteersYes

About this study

A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects

This description comes directly from the study's public registry record.

Talk to the study team

Wei Wang  ·  +86-010-60963099  ·  nvsiclinicaltrials@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shulan (Hangzhou) HospitalHangzhou, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07377175